China’s National Medical Products Administration鈥檚 Center for Drug Evaluation has granted to 鈥檚 repotrectinib for treating patients with NTRK-positive advanced solid tumours.
The designation is based on the data from the first-in-human, open-label, multi-centre Phase I/II TRIDENT-1 study in adults.
This registrational study is being carried out with , acquired by .
Zai Lab took part in the study in Greater China (mainland China, Hong Kong, Taiwan, and Macau) while Turning Point is enrolling patients globally.
Almost 500 pretreated participants aged 12 years and above with NTRK-positive TRK tyrosine kinase inhibitors (TKI) received oral repotrectinib.
The primary outcome measures of the study include dose-limiting toxicities, a recommended Phase II dose and the overall response rate.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataZai Lab global oncology research and development head and president Rafael Amado stated: 鈥淲e are excited to receive our fourth breakthrough therapy designation for repotrectinib in China.
“NTRK is estimated to be an oncogenic driver in approximately 0.5% of patients with a variety of advanced solid tumours. There remains an unmet medical need for NTRK-positive, TKI-pretreated advanced solid tumour patients where there are no targeted therapies currently approved.
鈥淲e look forward to working with regulatory authorities in China to bring this important medicine to patients in need as soon as possible.鈥�
